← Today’s ReceiptsOfficial public filing linked
Public-record receiptD-CAOfficial filing linked
Gilbert Cisneros disclosed BUY $LLY
Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.
Trade range
$1K – $15K
Filed
2026-05-08
Trade date
2026-04-14
Disclosure lag
24 days after trade
Why this receipt matters
A quick read before you share it.
These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.
1The receipt links to an official public filing, so readers can verify the underlying disclosure before sharing.
2The filing appeared 24 days after trade, which helps separate trade timing from filing timing.
3The disclosed range is $1K – $15K, which is the public reporting band rather than an exact profit or loss figure.
47 nearby same-ticker disclosures appeared in the surrounding 30-day window.
5Committee context is available for Gilbert Cisneros, but PoliWealth treats it as context - not proof of intent or wrongdoing.
6Related public-record context includes 32 lobbying filings and 1 federal contract record.
Source
Official filing ↗
Source: official House/Senate financial disclosure record · filing ID 20034500 · filed 2026-05-08 · disclosed 24d after transaction
Market context
Eli Lilly and Company
Sector: Healthcare
Vs SPY: 16.0%
Factual flags
- 32 lobbying filings linked to this ticker.
- 1 federal contract record linked to this ticker.
- 7 nearby same-ticker disclosures in the surrounding 30-day window.
- 95 trades filed on 2026-05-08 (batch dump)
- 3 members traded LLY within 7 days (starting 2026-04-08)
Member trail
Gilbert Cisneros
U.S. House · CA-31
House Committee on Armed ServicesHouse Committee on Small Business
Ticker trail
$LLY
Eli Lilly and Company
Follow this tickerAlert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.